Navigation Links
Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
Date:9/9/2008

cer of the Canadian Medical Discoveries Fund, a biotech venture capital fund. Dr. Stiller has authored more than 265 medical and scientific papers and has received a significant number of awards throughout his career for his medical contributions and entrepreneurship. Additionally, he has co-founded many organizations and programs including the Ontario Institute for Cancer Research.

In welcoming Dr. Stiller to Jennerex' board, Chairman Brennan Mulcahy commented that, "Dr. Stiller brings a wealth of medical and biotech experience to Jennerex, as well as extensive experience with emerging biotech companies. As Jennerex develops its corporate structure to support its clinical trials program, Dr. Stiller's counsel will be invaluable in guiding the board and management through a critical period in the company's development."

"I am excited to join the board of Jennerex at this exciting stage of its development," said Dr. Stiller. "The JX-594 lead product, as well as other offerings in this product class, have great potential to change cancer care and to develop significant market penetration for these novel therapeutics. I am very impressed with the Jennerex team which has made huge progress to date in a relatively short time, and with great efficiency in use of capital," added Dr. Stiller.

About JX-594

JX-594 is a cancer biotherapeutic, currently in Phase II trials, from a proprietary breakthrough class of targeted and armed oncolytic poxviruses. Tumor destruction and safety was shown in patients with diverse cancer types in three Phase I trials; treated patients were end-stage and had no effective therapies available. JX-594 multiplies selectively within cancer cells, leading to their destruction. These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells both locally and in distant sites in the body. This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeat
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
7. Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure
8. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
9. Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
10. NuVasive Completes Acquisition of Osteocel Biologics Business
11. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2014)... UMBC’s Biotechnology Graduate Programs’ Virtual ... 2014, from 12:00 to 1:00 p.m. EDT. The session ... and practice-oriented instruction, designed for working professionals. Participants will ... their career in the biotechnology industry. , If interested ... About UMBC’s Biotechnology Graduate Programs, UMBC offers a variety ...
(Date:9/13/2014)... Boehringer Laboratories Inc., with a forty year history ... successful broadcast of a live surgery by St. Luke’s ... FAMBS, and Maher El Chaar, MD, FACS, FAMBS, using ... This sleeve gastrectomy surgery was performed and broadcast live ... surgeons from around the world during the 5th International ...
(Date:9/12/2014)... Advancing the front lines of ... and biological threats is the mission of an ... (WPI) and the Georgian National Academy of Sciences, ... and Security Programme of the North Atlantic Treaty ... Workshop series, the event is titled “Nanotechnology to ...
(Date:9/12/2014)... On Thursday, September 11, 2014, the ... Industrial Average finished the day 0.12% lower at 17,049.00, and ... were broad based as seven out of ten sectors ended ... Index ended the day at 741.83, down 0.33%, while the ... has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
Breaking Biology Technology:UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... WILL BE FOR USE IN POINT-OF-CARE BONE MARROW PROCESSING, ... KOOL ), a leading supplier of innovative products ... said it has,received authorization from the FDA to begin ... laboratory setting or intraoperatively,for preparation of a cell concentrate ...
... water through point-of-use ... ultrafiltration, NEW ... device company, announced today that it will be exhibiting its,Dual Stage ... Technical Exhibition in National Harbor,Maryland, July 20th-23rd, 2008. Building on the ...
... July 14 Phlo Corporation,(Pink Sheets: PHCP) (the ... California of its vitality beverage, AQISS(TM),will be significantly ... of,the largest specialty beverage distributors in the San ... reached an agreement in principal with Morris,Distributing providing ...
Cached Biology Technology:ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 2ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 3ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM)) 4Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 2Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 3Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 4Phlo Affiliate Announces Significant Distribution Expansion In California 2
(Date:9/15/2014)... in the Department of Science and Technology in Society ... at Virginia Tech, has won a 2014 National Science ... prospects and problems of creating a global nuclear emergency ... I Nuclear Power Plant in March 2011 was a ... emergencies, Schmid said. Three of the plant,s six nuclear ...
(Date:9/15/2014)... the oceans, there must be enough dissolved oxygen ... oxygen-starvation produces "dead zones" that decimate marine fisheries ... levels decline, energy is increasingly diverted away from ... impacts on the ecology and biogeochemistry of the ... minimum zones (OMZs) have expanded due to climate ...
(Date:9/15/2014)... and cognitive function may play roles in one,s musical ... pitch, timbre, tone durations, and formal structure in music. ... explain that extremes in musical aptitude (extreme capacity/no capacity) ... individuals having moderate aptitude. , "This is a typical ... genes, and it is influenced to varying degrees by ...
Breaking Biology News(10 mins):'Nuclear disasters don't respect national boundaries' 2Decoding virus-host interactions in the oxygen-starved ocean 2Decoding virus-host interactions in the oxygen-starved ocean 3Decoding virus-host interactions in the oxygen-starved ocean 4Decoding virus-host interactions in the oxygen-starved ocean 5
... Established in 2007 and based in Toronto, ArcticDx has ... kind and specifically designed to determine one,s inherited risk ... of acquired blindness in the developed world, affecting over ... investment to undertake studies in support of a planned ...
... One of the many advantages of maintaining a normal body ... healthy heart. Fat tissue is increasingly seen as more than ... organ that normally produces high levels of a cardioprotective hormone ... has long been a mystery, and now a team led ...
... the Morrison Natural History Museum have again discovered infant ... near the town of Morrison. Dating from the Late ... made before the Rocky Mountains rose, when Morrison was ... tracks represent infant sauropods, according to discoverer Matthew Mossbrucker, ...
Cached Biology News:OGI invests in personalized medicine for age-related macular degeneration 2Study finds fat hormone's long-sought link to heart protection 2Morrison Natural History Museum discovers baby sauropod tracks 2Morrison Natural History Museum discovers baby sauropod tracks 3
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Direct ELISA Assay Diluent - EDTA, 10 L...
... gel electrophoresis into an automated, high-throughput operation ... pre-cast system is ideal for analyzing multiple ... more. Fully automated, robot-compatible, and ready to ... makes your high-throughput screening assignments as easy ...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Biology Products: